Lori Friedman

Author PubWeight™ 14.54^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Systematic generation of high-resolution deletion coverage of the Drosophila melanogaster genome.	Nat Genet	2004	8.24
2	Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer.	Proc Natl Acad Sci U S A	2009	2.77
3	Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer.	J Med Chem	2011	1.08
4	A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal.	Clin Cancer Res	2012	1.05
5	Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer.	J Med Chem	2010	0.99
6	Rethinking healthy families: a continuous responsibility.	Child Abuse Negl	2005	0.75
7	Corrigendum: Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer.	Nature	2016	0.75